Want to see CBUS full AI Analyst Report?
CBUS Stock Chart & Stats
$1.70
$0.04(2.65%)
At close: 4:00 PM EDT
$1.70
$0.04(2.65%)
Day’s Range― - ―
52-Week Range$1.09 - $4.19
Previous CloseN/A
Volume30.60K
Average Volume (3M)154.04K
Market Cap
$147.32M
Enterprise Value$374.93
Total Cash (Recent Filing)$30.32M
Total Debt (Recent Filing)$276.15M
Price to Earnings (P/E)―
Beta2.96
Next Earnings
Aug 13, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding76,331,635
10 Day Avg. Volume164,630
30 Day Avg. Volume154,044
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)36.47
Price to Sales (P/S)218.79
P/FCF Ratio-15.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.00Price Target Upside1370.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.18
Revenue Forecast (FY)$8.05M
Bulls Say, Bears Say
Bulls Say
Platform & Editing EfficiencyCibus's Trait Machine achieved a step-change in editing efficiency and single-cell regeneration in wheat. This durable platform advancement increases throughput, shortens development cycles, lowers per-trait costs, and broadens crop applicability, supporting scalable trait pipelines and long-term commercial optionality.
LATAM Commercial TractionConcrete commercial actions in LATAM — LOI, import permit, delivery of edited materials and seven active seed relationships — create a tangible early revenue pathway. Regional deployment in 2027 and equivalence determinations reduce regulatory friction and diversify commercialization beyond U.S. timing risk.
Expense Discipline & RunwaySignificant capital raises plus meaningful reductions in R&D and SG&A materially extended runway into late Q1 2027. The combined effect of fresh capital and cost discipline reduces near-term financing pressure and gives management time to execute commercial launches and convert pilots into revenue.
Bears Say
High Cash BurnPersistent, large absolute cash outflows relative to a small revenue base mean ongoing funding needs. Sustained burn increases probability of future dilution or restrictive financing, limits discretionary investment in scale-up, and places pressure on meeting commercialization milestones without additional capital.
Deep Losses & Weak ProfitabilityExtreme negative margins and outsized operating losses indicate the business is far from breakeven. Continued erosion of returns and interest on royalty liabilities reduce equity resilience, constrain reinvestment, and heighten reliance on external capital until margins sustainably improve.
Early-Stage Partnerships & Revenue UncertaintyMany commercialization arrangements remain non‑binding or early-stage, meaning revenue timing and scale are uncertain. Coupled with a U.S. launch delay tied to third-party herbicide registration, this structural dependency on partner execution and external approvals raises the risk that expected royalties may be delayed or diminished.
Cibus News
CBUS FAQ
What was Cibus’s price range in the past 12 months?
Cibus lowest stock price was $1.09 and its highest was $4.19 in the past 12 months.
What is Cibus’s market cap?
Cibus’s market cap is $147.32M.
When is Cibus’s upcoming earnings report date?
Cibus’s upcoming earnings report date is Aug 13, 2026 which is in 10 days.
How were Cibus’s earnings last quarter?
Cibus released its earnings results on May 14, 2026. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.27 by -$0.06.
Is Cibus overvalued?
According to Wall Street analysts Cibus’s price is currently Undervalued.
Does Cibus pay dividends?
Cibus does not currently pay dividends.
What is Cibus’s EPS estimate?
Cibus’s EPS estimate is -0.24.
How many shares outstanding does Cibus have?
Cibus has 76,331,635 shares outstanding.
What happened to Cibus’s price movement after its last earnings report?
Cibus reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.27. Following the earnings report the stock price went down -7.092%.
Which hedge fund is a major shareholder of Cibus?
Currently, no hedge funds are holding shares in CBUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cibus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (1370.59% Upside)
$25.00 (1370.59% Upside)
Hedge Fund Trend
Decreased
By 22.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 9.7%
Last 30 Days ▲ 9.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.24%
Trailing 12-Months
Company Description
Cibus
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
CBUS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized execution: material commercial progress in LATAM rice (LOI, import permit, delivery of edited materials), clear technical advances (order-of-magnitude improvement in editing efficiency; wheat single-cell regeneration), regulatory tailwinds, and tangible cost reductions that materially improved the P&L and extended runway after raising ~ $37M gross. Offsets include a limited cash runway into Q1 2027 absent stronger near-term revenue, a U.S. rice launch delay from 2028 to 2029 due to herbicide registration timing, continued sizable quarterly net losses and interest on royalty liabilities, and several commercial arrangements still at LOI or early stages. Overall, the positives (capital raise, execution on priority programs, technical and regulatory momentum, and meaningful expense reductions) outweigh the negatives, though the company's trajectory remains execution-dependent.View all CBUS earnings summariesCBUS Stock 12 Month Forecast
Average Price Target
$25.00
▲(1370.59% Upside)
Technical Analysis
Ownership Overview
25.66% Insiders
9.60% Mutual Funds
0.56% Other Institutional Investors
60.93% Public Companies and
Individual Investors